Conference report: Bio-International 2005.
This is a summary report of the International Pharmaceutical Federation/Board of Pharmaceutical Sciences (FIP/BPS) international conference, Bio-International 2005, which was held October 24-26, 2005 at the Royal Pharmaceutical Society, in London, UK. Bioequivalence (BE) issues related to multisource locally delivered topical dosage forms, oral inhalation drug products, highly variable drug products (HVDP), and endogenously occurring drugs were discussed. The conference also focused on alternate approaches to assess BE for some of these drug products. Pharmacokinetic (PK) approaches like, dermatopharmacokinetics (DPK) for dermatological topical dosage forms, scaled average BE (s-ABE) where within-subject variability is considered for estimation of 90% confidence intervals to document BE for highly variable drugs (HVD) were recommended. In addition, issues and difficulties related to the BE assessment of oral inhalation products, role, and appropriateness of metabolites in BE assessment, importance of base line correction in BE assessment of endogenously occurring drugs, and waiver of BE study requirements for certain drugs based on a Biopharmaceutics Classification System (BCS), were also discussed.
Midha
Kamal K
KK
College of Pharmacy and Medicine, University of Saskatchewan, Saskatoon, SK, Canada. midha@pharmalytics.ca
Shah
Vinod P
VP
Singh
Gur Jai Pal
GJ
Patnaik
Rabi
R
D000280:Administration, Inhalation; D000287:Administration, Topical; D001682:Biological Availability; D001702:Biopharmaceutics / Q000145:classification; D006801:Humans; D013810:Therapeutic Equivalency